Back to search results

Ruxolitinib for Relapsed or Refractory T or NK Cell Lymphoma

This study is testing a drug called ruxolitinib in people with T or NK cell lymphoma that has come back or not responded to previous treatments. Ruxolitinib works by blocking a protein called JAK, which helps these lymphoma cells survive. By blocking JAK, ruxolitinib might cause the lymphoma to shrink. The study aims to see how many people experience disease control (meaning the lymphoma doesn't grow or shrinks) over two years. You may be able to join if you are 18 or older, have T or NK cell lymphoma confirmed by a doctor, and your lymphoma has relapsed or didn't respond to at least one prior treatment. The study plans to enroll 83 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 83 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure disease control for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02974647

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~83 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Ruxolitinib

At a glance

Recruiting sites
6 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
disease control rate
Measured over 2 years

Conditions

Lymphoma

Explore related trials

Nasal Type Extranodal NK/T-Cell LymphomaT-Cell Non-Hodgkin Lymphoma

NCT02974647

Where you'd take part

This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Commack

    Commack, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Monmouth (All Protocol Activities)

    Middletown, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Nassau (All Protocol Activities)

    Uniondale, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Westchester

    Harrison, New Yorkstudy coordinator listed

    Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusettsno site contact published

    Active, not recruiting

  • Northwestern Medicine (Data collection and specimen analysis)

    Chicago, Illinoisno site contact published

    Active, not recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Alison Moskowitz, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Alison Moskowitz, MD
212-639-4839
Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pathologically confirmed T or NK cell lymphoma at the enrolling institution. For CTCL, patients with stage IB disease or greater are eligible.
Relapse or refractory disease after at least 1 systemic therapy except for T-PLL, LGL, or T-cell Lymphoproliferative diseases with JAK2 fusion.
Untreated patients may be allowed after discussion with P.I.
Age ≥ 18
ECOG ≤ 2
Measurable disease defined by:
Lugano Classification for systemic lymphoma or
Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood or bone marrow or
mSWAT \> 0 or Sezary count ≥ 1000 cells/μL for CTCL
Previous systemic anti-cancer therapy for T-cell lymphoma must have been discontinued at least 2 weeks prior to treatment.
Glucocorticoids aimed at controlling lymphoma-related symptoms are allowed as long as they are tapered down to 20mg or less by the time of ruxolitiib initiation
Topical steroids for CTCL are permitted

Exclusion

Patients must meet the following lab criteria:
ANC ≥ 1.0/mm\^3 or ANC \>/= 0.5/mm\^3 (if patient has baseline neutropenia due to lymphoma), platelets ≥ 100 x 10\^9/L or ≥ 50 x 10\^9/L (if related to lymphoma), Hgb ≥ 8g/dL
Patients with LGL or T-PLL are not required to meet a minimum ANC or hemoglobin value for eligibility
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or; ≤ 3 x ULN if documented hepatic involvement with lymphoma, or ≤ 5 x ULN if history of Gilbert's ; AST and ALT ≤ 3 x ULN; ≤ 5 x ULN if due to lymphoma involvement
Creatinine clearance ≥ 30 mL/min; creatinine clearance of 15-29 mL/min will be allowed as long as baseline platelets are ≥ 150 x 10\^9/L
For patients with positive hepatitis B core antibody or surface antigen, hepatitis B PCR must be negative and prophylaxis with entecavir or equivalent is required.
Patients with HIV are allowed provided that they are on anti-retroviral treatment with no active infections.
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, uncontrolled diabetes, clinically significant pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
ECOG performance status \>2
Prior therapy with ruxolitinib
Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma)
Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator
Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK principal Investigator
Women of reproductive potential† must have a negative Serum ß human chorionic gonadotropin (ß-HCG) pregnancy test.
A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).

What this trial measures

  • disease control rate2 years

    defined as the combination of complete response (CR), partial response (PR) and stable disease (SD). The reason we use this definition instead of the more conventional partial/complete response rate is twofold.